title: Combination of recombinant xenogeneic endoglin DNA and protein vaccination enhances anti-tumor effects.
abstract: The immunization approaches with DNA vaccine priming and subsequent protein or peptide boosting has been widely tested in various models of infectious diseases. However, these approaches are seldom reported in the areas of cancer immunotherapy. In this study we combined endoglin plasmid DNA and recombinant protein as vaccines and used them to prime and boost, simultaneously, as a vaccine strategy. Our results showed that combination of endoglin DNA and protein vaccines could enhance both protective and therapeutic anti-tumor efficacy in both colon carcinoma and Lewis lung carcinoma models. Significant inhibition of tumor angiogenesis was found in the tumor tissues. The titers of autoantibodies against murine endoglin were significantly increased and the antibody levels lasted longer in the mice with combined endoglin DNA and recombinant protein vaccination. CTL response against endoglin-positive HUVECs, but not against endoglin-negative tumor cells was found in the mice combined DNA with protein vaccination. In addition, combination of endoglin DNA and recombinant protein vaccination significantly induced IFN-gamma secreting cells. These observations suggested that a combination of endoglin DNA and recombinant protein immunization as a vaccine strategy was superior to those using endoglin DNA or recombinant protein alone as vaccines.
authors: Hainan Provincial Key Laboratory of Tropical Medicine, Hainan Medical College, Haikou, People's Republic of China. tanhoho@163.com
authors: Guang-Hong
authors: GH
authors: Tan
authors: Yue-Nan
authors: YN
authors: Li
authors: Feng-Ying
authors: FY
authors: Huang
authors: Hua
authors: H
authors: Wang
authors: Rui-Zhen
authors: RZ
authors: Bai
authors: Jie
authors: J
authors: Jang
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use; D018827:Carcinoma, Lewis Lung / Q000098:blood supply / Q000276:immunology* / Q000628:therapy; D015179:Colorectal Neoplasms / Q000098:blood supply / Q000276:immunology* / Q000628:therapy; D000071063:Endoglin; D007115:Immunization Schedule; D007371:Interferon-gamma / Q000276:immunology / Q000378:metabolism; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009389:Neovascularization, Pathologic; D011994:Recombinant Proteins / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology / Q000378:metabolism; D019444:Vaccines, DNA / Q000276:immunology* / Q000627:therapeutic use
chemical_list: D019496:Cancer Vaccines; D000071063:Endoglin; C502004:Eng protein, mouse; D047908:Intracellular Signaling Peptides and Proteins; D011994:Recombinant Proteins; D019444:Vaccines, DNA; D007371:Interferon-gamma